GeneDx Holdings (WGS) Return on Sales (2020 - 2026)

GeneDx Holdings (WGS) has reported Return on Sales for 7 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Sales fell 1.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Sales fell to 0.01% in Q1 2026 per WGS's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q2 2025 and bottomed at 0.05% in Q4 2022.
• Historically, Return on Sales has averaged 0.01% across 5 years, with a median of 0.0% in 2023.
• Annual changes were most pronounced in 2022 — Return on Sales decreased 4 bps — and 2023, when it climbed 5 bps.
• GeneDx Holdings' Return on Sales stood at 0.05% in 2022, then jumped by 91 bps to 0.0% in 2023, then jumped by 113 bps to 0.0% in 2024, then sank by 356 bps to 0.0% in 2025, then slumped by 324 bps to 0.01% in 2026.
• Business Quant data shows WGS's Return on Sales at 0.01% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.